159 related articles for article (PubMed ID: 34983084)
1. Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine-based delivery applications and future trends.
Abdelhakeem E; El-Nabarawi M; Shamma R
Br J Clin Pharmacol; 2022 Jun; 88(6):2665-2672. PubMed ID: 34983084
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.
Bousquet E; Zhao M; Daruich A; Behar-Cohen F
Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
[TBL] [Abstract][Full Text] [Related]
4. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
Yang D; Eliott D
Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Zhao M; Célérier I; Bousquet E; Jeanny JC; Jonet L; Savoldelli M; Offret O; Curan A; Farman N; Jaisser F; Behar-Cohen F
J Clin Invest; 2012 Jul; 122(7):2672-9. PubMed ID: 22684104
[TBL] [Abstract][Full Text] [Related]
6. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
Lotery A; Sivaprasad S; O'Connell A; Harris RA; Culliford L; Ellis L; Cree A; Madhusudhan S; Behar-Cohen F; Chakravarthy U; Peto T; Rogers CA; Reeves BC;
Lancet; 2020 Jan; 395(10220):294-303. PubMed ID: 31982075
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
[TBL] [Abstract][Full Text] [Related]
8. [Eplerenone treatment in chronic central serous chorioretinopathy].
Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
[TBL] [Abstract][Full Text] [Related]
9. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.
Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP
Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056
[TBL] [Abstract][Full Text] [Related]
11. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report.
Gruszka A
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1369-73. PubMed ID: 23740451
[TBL] [Abstract][Full Text] [Related]
12. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
Venkatesh R; Pereira A; Jain K; Yadav NK
BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
[TBL] [Abstract][Full Text] [Related]
14. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
[TBL] [Abstract][Full Text] [Related]
15. Effect of eplerenone on choroidal blood flow changes during isometric exercise in patients with chronic central serous chorioretinopathy.
Gallice M; Daruich A; Matet A; Mouvet V; Dirani A; Evequoz G; Geiser M; Behar Cohen F; Chiquet C
Acta Ophthalmol; 2021 Dec; 99(8):e1375-e1381. PubMed ID: 33650207
[TBL] [Abstract][Full Text] [Related]
16. Oral medications for central serous chorioretinopathy: a literature review.
Fusi-Rubiano W; Saedon H; Patel V; Yang YC
Eye (Lond); 2020 May; 34(5):809-824. PubMed ID: 31527760
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
Kapoor KG; Wagner AL
Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
[TBL] [Abstract][Full Text] [Related]
18. Should We Stop Treating Patients With Eplerenone for Chronic CSCR? Commentary on the VICI Trial.
Daugirdas SP; Bheemidi AR; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):308-310. PubMed ID: 34185584
[TBL] [Abstract][Full Text] [Related]
19. Eplerenone for chronic central serous chorioretinopathy.
Stanescu-Segall D; Touhami S; Bodaghi B; LeHoang P
Lancet; 2020 Nov; 396(10262):1556-1557. PubMed ID: 33189169
[No Abstract] [Full Text] [Related]
20. Eplerenone for chronic central serous chorioretinopathy.
Sacconi R; Borrelli E; Querques G
Lancet; 2020 Nov; 396(10262):1556. PubMed ID: 33189168
[No Abstract] [Full Text] [Related]
[Next] [New Search]
